Using a reduced-intensity stem cell transplantation (RIST) schedule, 24 patients with Philadelphia (Ph1) ( þ ) chronic myelogenous leukemia (CML) in first chronic phase (CP) were prospectively allografted in four Latin American countries: Me´xico, Brazil, Colombia and Venezuela, using HLA-identical siblings as donors. The median age of the patients was 41 years (range 10-71 years); there were eight females. Patients received a median of 4.4 Â 10 6 /kg CD34 cells. The median time to achieve above 0.5 Â 10 9 /l granulocytes was 12 days, range 0-41 days, and the median time to achieve above 20 Â 10 9 /l platelets was also 12 days, range 0-45 days. In all, 22 patients are alive 81-830 (median 497) days after RIST. The 830-day probability of survival is 92%, and the median survival has not been reached, being beyond 830 days. A total of 11 patients (46%) developed acute graftversus-host disease (GVHD), and seven of 23 (30%) developed chronic GVHD. Two patients died 43 and 210 days after RIST, one as a result of sepsis and the other of chronic GVHD. The 100-day mortality was 4.4%, and transplant-related mortality was 8%. RIST for patients with CML in CP appears to be an adequate therapeutic option.
reduced intensity
Chronic myelogenous leukemia (CML) is a deceptive leukemia because in its chronic phase (CP) evolves with a rather benign phenotype; however, its invariable transformation to the acute blast crisis endows the disease with true malignant character. [1] [2] The ultimate goal of the treatment of patients with CML is to induce both cytogenetic and molecular remissions; cytogenetic remissions can be obtained with interferon or imatinib, and molecular remissions can be achieved with allogeneic bone marrow transplantation, which, largely because of its limited application to young patients with a suitable donor, only 'cures' about 15% of all patients with the disease. [1] [2] [3] The rationale behind reduced-intensity stem cell transplantation (RIST) is to induce optimal graft-versusleukemia (GVL) effects for elimination of all malignant cells by donor alloreactive-immunocompetent cells as an alternative to standard high-dose myeloablative chemoradiotherapy. [4] [5] [6] [7] CML is one of the most sensitive malignancies to the GVL effect, 8 and studies describing the usefulness of RIST in both CP and accelerated phase of the disease have been published. [6] [7] In 2002, we published a report on 21 patients with CML who were given an RIST, 6 using the 'Mexican approach', 4,9 which employs fludarabine, busulfan and cyclophosphamide; in that series, individuals with different phases of the disease (CP, blastic and accelerated phases) were included. We report herein a multicenter, Latin American, prospective experience, using the same conditioning regimen, [4] [5] [6] in a group of 24 patients with CML in first CP. As expected, the results were clearly better than those obtained previously in different phases of the malignancy.
Materials and methods

Patients and donors
All the patients with Philadelphia (Ph1) chromosome and/ or BCR/ABL (p210)-positive CML in CP, allografted in Table 1 shows some of the patients' salient features. None of these patients was included in the previous publication. 6 In all, 17 patients had received hydroxyurea, nine had received imatinib for 10-50 months (median 28 months) before RIST and three had received interferon; six of them had high-risk characteristics. All patients were in a hematological remission and had a Karnofsky score of 100% at the time the procedure was performed. The donor was an HLA-identical (6/6) sibling in all instances. Institutional review board approval and written consent was obtained from all the individuals.
HSC mobilization and apheresis
G-CSF (10 mg/kg/day) was delivered to the sibling donors on day À5 to þ 2. One to three apheresis procedures were planned for on days 0, þ 1 and þ 2 by means of a Haemonetics V-50 PLUS machine (Haemonetics Corporation, Braintree, MA, USA), a Baxter C-3000 PLUS machine (Baxter Healthcare, Deerfield IL, USA), an AMICUS (Baxter Healthcare, Deerfield, IL, USA) or a COBE-Spectra (Gambro, Lakewood, CO, USA) using the Spin-Nebraska protocol. 10 The end point of collection was the processing of 5000-7000 ml of blood/m 2 in each of the three apheresis procedures, [4] [5] [6] in order to obtain at least 5 Â 10 8 mononuclear cells and/or 2 Â 10 6 viable CD34 cells/kg of the recipient's weight.
Conditioning and grafting
A simplification of the low-intensity conditioning regimens described by Giralt et al 11 and Slavin et al 12 was used as described previously:
4-6 oral busulfan, 4 mg/kg, was delivered on days À6 and À5; intravenous (i.v.) cyclophosphamide, 350 mg/m 2 , on days À4, À3 and À2; i.v. fludarabine, 30 mg/m 2 , on days À4, À3 and À2; oral cyclosporin A (CyA), 5 mg/kg, was started on day À1; and i.v. methotrexate 5 mg/m 2 was delivered on days þ 1, þ 3, þ 5 and þ 11. Oral CyA was continued through day 180, with adjustments according to obtain serum CyA levels of 150-275 ng/ml; it was then tapered over 30-60 days. If graft-versus-host disease (GVHD) data were present, the CyA tapering was carried out over longer periods. Ondansetron (1 mg i.v. every hour during 4 h after i.v. chemotherapy), an oral quinolone and an azole were used in all patients following each center recommendation; antibiotics and antimycotics were used until more than 500 granulocytes/ml were present. The products of the PBSC apheresis were reinfused on days 0-2. Donor lymphocyte infusions were given 100 days after the allografts only if no evidence of GVHD was present and if there were data of leukemic activity or relapse.
Apheresis product studies
Enumeration of the total white blood, mononuclear (MNC) and CD34-positive cells was carried out by flow 
Molecular biology studies
In cases with a sex mismatch, a fluorescent in situ hybridization technique to demonstrate the X and Y chromosomes 15 was carried out; in cases with ABO system mismatch, a flow-cytometry-based approach was used, and polymorphic markers (STRs) 16 were analyzed in the absence of the previously mentioned mismatches. The BCR/ABL-specific transcripts were detected by nonquantitative multiplex RT-PCR; details of the method have been published previously. 3, 17 The sensitivity for the detection of the BCR/ABL transcripts is about 10 À5 as has been determined previously by dilution experiments with K562 cells. The molecular biology studies were carried out at diagnosis, at 30 days after the allograft and every 3-6 months thereafter. Survival was calculated according to Kaplan and Meier.
Results
In all, 24 patients with CML in CP were allografted; eight were female ( Table 1 ). The median age was 41 years (range 10-71 years). The median time from diagnosis to allograft was 570 days (range 60-3480 days). Patients received a median of 4.4 Â 10 6 /kg CD34 ( þ ) cells, using one to three (median 2) apheresis procedures. The median time to achieve 40.5 Â 10 9 /l granulocytes was 12 days, range 0-41 days, and median time to achieve 420 Â 10 9 /l platelets was also 12 days, range 0-45 days. A total of 22 patients are alive 81-830 (median 497) days after RIST. The 830-day survival is 92%, and median survival has not been reached, being 4830 days (Figure 1 ). Acute GVHD was defined as that occurring before day 100; 11 patients (46%) developed acute GVHD (five cases grade I and six grade II), while seven of 23 (30%) developed chronic GVHD. In one instance (case 4), chronic GVHD was fatal despite intensive immunosuppression and extracorporeal photopheresis.
Two patients (numbers 1 and 4) died 43 and 210 days after RIST, one as a result of sepsis and the other of chronic GVHD. All patients maintained hematological remission; in 18 patients, a molecular remission (disappearance of the BCR/ABL fusion transcript) was recorded, and in five patients in whom it was not possible to test for the BCR/ABL transcript, a complete cytogenetic response was achieved. All the patients who cleared the BCR/ABL fusion transcript were assessed for chimerism and found to be full chimeras. One patient (number 19) has never cleared the BCR/ABL fusion transcript despite a cytogenetic response; she remains in hematological remission, being a mixed chimera (60% donor cells) 22 months after the allograft; she has been given donor lymphocyte infusions in three instances and receives imatinib. Serial data on the kinetics of the BCR/ABL fusion transcript were not available in all patients; however, in a subset of 18 patients (those tested for the BCR/ABL fusion transcript), the transcript was cleared 30-240 days (median 120 days) after the allograft. The 100-day mortality was 4.4% (one of 23), and the transplant-related mortality was 8%. Two patients (numbers 7 and 29) experienced a relapse 6 and 20 months after the allograft and are receiving imatinib. Seven patients experienced mucositis, which was severe in one, and three had infectious complications: a cutaneous herpes zoster, a Staphylococcus epidermidis cellulitis in the catheter-insertion site and a nonfatal cytomegalovirus enteritis. Two patients were admitted to hospital as a result of neutropenic fever, which resolved with intravenous antibiotics; in 19 patients the entire procedure was completed on an outpatient basis.
Discussion
Standard treatment options for patients with CML are allogeneic BMT, imatinib, hydroxyurea, interferon-alphabased regimens and busulfan; however, the only really curative treatment modality for these patients is allogeneic BMT. 18 Allogeneic BMT has become an option to be considered less frequently than before the imatinib era. 18 In developing countries, imatinib is available free only to few individuals. The median cost of the first 100 days after an allogeneic RIST in Me´xico is 18 000 USD; 4, 6, 9, 19 with this sum, 200 days of continued treatment with imatinib can be provided at 400 mg/day. 6, 8 Accordingly, many individuals in Me´xico and other developing countries elect to have an allogeneic RIST for economic reasons rather than other arguments. Despite the fact that we do not have detailed data about the cost of giving RIST to patients in other developing countries, the costs seem to be similar to those calculated for Me´xico. In the young CML patient, other reasons for considering a bone marrow allograft are uncertainty about both the prolonged use of imatinib or the availability of a suitable donor, when identified.
Allogeneic RIST has been shown to be useful in individuals with CML. 6, 7, [20] [21] [22] We published in 2002 the first series of patients in Me´xico with CML given an RIST; in that group, we included individuals with CP, accelerated and blastic phases. 6 Later, Or et al, they found a 5-year overall survival (OS) of 85%. 7 More recently, Weisser et al, 20 in Germany reported their experience in 35 elderly CML given RIST in different phases of the disease, emphasizing the benefit of early transplantation, within the first year of diagnosis. Other authors have included CML patients in their reports of RIST. 22 The data in this paper indicate that the results of our approach to conduct RIST 4-6 could be reproduced in patients with CML in other developing Latin American countries, specifically Colombia, Venezuela and Brazil. The results in this group of individuals were, as expected, better than those we obtained some years ago, 6 because we have now included only patients in CP; in this context, our results are comparable to those obtained by Or et al 7 in Jerusalem; they found a 5-year OS of 85%, whereas we have found an 830-day probability of survival of 92%; however, it has to be taken into account that follow-up of the patients in this study is still short.
Our data and that from others indicate that RIST is effective for allografting individuals with CML; [6] [7] [20] [21] [22] [23] [24] [25] despite the fact that most studies with reduced-intensity conditioning have a relatively short follow-up, there is information indicating that the procedure has a lower prevalence and severity of GVHD, 26 and similar efficacy to conventional allografting; the low prevalence of chronic GVHD in this study supports this observation, which may be related to the diminished organ damage induced by the conditioning schedule. Since this method is more feasible and affordable for patients and physicians in developing countries, the number of allografts in these places has increased substantially, as well as the publications related to bone marrow transplantation stemming from places where this therapeutic maneuver was considered as unaffordable previous to the development of this technology. 19 Despite the fact that allografting with reducedintensity conditioning may have several disadvantages such as mixed chimerism and relapse of the malignancy, RIST has resulted in the accessibility of many CML patients to sophisticated therapeutic options, in some cases, the only true curative option for these individuals. At least in developing countries, RIST has resulted in reconsidering the place of other CML treatments such as imatinib, within the therapeutic armamentarium of hemato-oncologists.
